Form 4: Ionis Director Exercises Options, Sells Shares

Ionis Pharmaceuticals Director Joseph Loscalzo exercised stock options and subsequently sold 16,000 shares of common stock for a profit, as per a pre-arranged 10b5-1 trading plan.

Summary

• Director Joseph Loscalzo exercised non-qualified stock options to acquire 16,000 shares of Ionis Pharmaceuticals common stock at an exercise price of $24.42 per share on September 3, 2025.
• Concurrently, Mr. Loscalzo sold 16,000 shares of common stock at a weighted average price of $60.1482 per share on September 3, 2025, with individual transaction prices ranging from $60.00 to $60.57.
• The sale was executed under a Rule 10b5-1 trading plan that the reporting person adopted on August 13, 2024.
• Following these transactions, Mr. Loscalzo directly beneficially owns 36,330 shares of Ionis Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The director's exercise of options and subsequent sale of shares, while reducing direct ownership, was executed under a pre-arranged 10b5-1 plan, indicating a systematic approach to personal financial management rather than a reaction to company-specific news. The significant profit realized from the option exercise also reflects positively on the stock's performance.

Positives

• The director realized a significant profit from the option exercise and subsequent sale, with the sale price of $60.1482 per share being substantially higher than the exercise price of $24.42 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a systematic approach to managing personal holdings rather than a reaction to immediate company news.

Negatives

• A director selling shares reduces their direct ownership stake, which some investors might interpret as a minor negative, although mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the transaction as a director taking profits, which is a routine event, especially when conducted under a 10b5-1 plan, mitigating concerns about the director's confidence in the company.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction (option exercise and sale under a 10b5-1 plan) by a director. While the director realized a significant profit, this type of transaction is generally not indicative of a change in the company's fundamental outlook or performance. Therefore, it does not provide sufficient new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Options, Share Sale, Joseph Loscalzo, 10b5-1 Plan